Global Entrectinib Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Entrectinib Market Research Report 2024
Entrectinib, also known as RXDX-101 and NMS-E628, is an oral small molecule inhibitor of TrkA, TrkB and TrkC, as well as ROS1 and ALK, with high potency and selectivity. RXDX-101 has demonstrated potent pharmacological activity in preclinical studies and has the potential to be first-in-class against the Trk family of kinases. PXDX-101 has been well tolerated in patients with advanced solid tumors. PXDX-101 is currently in clinical trials, and is being developed by Ignyta.
According to Mr Accuracy reports’s new survey, global Entrectinib market is projected to reach US$ million in 2034, increasing from US$ million in 2024, with the CAGR of % during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Entrectinib market research.
Key manufacturers engaged in the Entrectinib industry include BOCSCI, APExBIO Technology, Cayman Chemical, ChemScence, Crysdot, Medical Isotopes, TargetMol Chemicals, Toronto Research Chemicals and Beijing Jingming Biotechnology, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2024.
When refers to consumption region, % volume of Entrectinib were sold to North America, Europe and Asia Pacific in 2024. Moreover, China, plays a key role in the whole Entrectinib market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Entrectinib market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
BOCSCI
APExBIO Technology
Cayman Chemical
ChemScence
Crysdot
Medical Isotopes
TargetMol Chemicals
Toronto Research Chemicals
Beijing Jingming Biotechnology
Cool Pharm
Shanghai Lollane Biological Technology
Shanghai Macklin Biochemical
Shanghai Muse Health Tech
ATK Chemical
Shanghai Send Pharmaceutical Technology
Shanghai Yuanye Bio-Technology
Wuhan Sun-Shine Bio-Technology
Segment by Type
0.99
0.98
Anaplastic Lymphoma
C-ros Oncogene
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Entrectinib report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Entrectinib market is projected to reach US$ million in 2034, increasing from US$ million in 2024, with the CAGR of % during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Entrectinib market research.
Key manufacturers engaged in the Entrectinib industry include BOCSCI, APExBIO Technology, Cayman Chemical, ChemScence, Crysdot, Medical Isotopes, TargetMol Chemicals, Toronto Research Chemicals and Beijing Jingming Biotechnology, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2024.
When refers to consumption region, % volume of Entrectinib were sold to North America, Europe and Asia Pacific in 2024. Moreover, China, plays a key role in the whole Entrectinib market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Entrectinib market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
BOCSCI
APExBIO Technology
Cayman Chemical
ChemScence
Crysdot
Medical Isotopes
TargetMol Chemicals
Toronto Research Chemicals
Beijing Jingming Biotechnology
Cool Pharm
Shanghai Lollane Biological Technology
Shanghai Macklin Biochemical
Shanghai Muse Health Tech
ATK Chemical
Shanghai Send Pharmaceutical Technology
Shanghai Yuanye Bio-Technology
Wuhan Sun-Shine Bio-Technology
Segment by Type
0.99
0.98
Segment by Application
Anaplastic Lymphoma
C-ros Oncogene
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Entrectinib report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source